2.40
Precedente Chiudi:
$2.38
Aprire:
$2.4
Volume 24 ore:
6,882
Relative Volume:
0.27
Capitalizzazione di mercato:
$16.85M
Reddito:
-
Utile/perdita netta:
$-7.72M
Rapporto P/E:
-0.9093
EPS:
-2.6394
Flusso di cassa netto:
$-6.25M
1 W Prestazione:
+1.27%
1M Prestazione:
+20.00%
6M Prestazione:
+7.62%
1 anno Prestazione:
-50.00%
Edesa Biotech Inc Stock (EDSA) Company Profile
Nome
Edesa Biotech Inc
Settore
Industria
Telefono
(905) 475-1234
Indirizzo
100 SPY COURT, MARKHAM, ON
Confronta EDSA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EDSA
Edesa Biotech Inc
|
2.40 | 17.07M | 0 | -7.72M | -6.25M | -2.6394 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Edesa Biotech Inc Borsa (EDSA) Ultime notizie
What drives Edesa Biotech Inc. stock priceTriple-digit returns - PrintWeekIndia
What analysts say about Edesa Biotech Inc. stockExceptional earning trajectories - Autocar Professional
Edesa Biotech Inc. Stock Analysis and ForecastConsistent double returns - jammulinksnews.com
Is Edesa Biotech Inc. a good long term investmentOverwhelming profit margins - Autocar Professional
Edesa Biotech Insiders May Regret Not Buying More, Market Cap Hits US$16m - simplywall.st
What makes Edesa Biotech Inc. stock price move sharplyElite Stock Shortlist - Newser
How Edesa Biotech Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
Why Edesa Biotech Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - Newser
Edesa Biotech's JUST BREATHE Study Advances ARDS Treatment with Promising Progress - AInvest
Edesa Biotech Advances ARDS Treatment with JUST BREATHE Study - TipRanks
Edesa Biotech (NASDAQ:EDSA) Shares Down 1% – Here’s Why - Defense World
H.C. Wainwright Maintains Edesa Biotech(EDSA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Edesa Biotech secures up to C$23 million in funding under the Federal Government’s Strategic Innovation Fund for pivotal clinical study - Fasken
Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares - Fasken
Edesa Biotech completes US$15 million private placement - Fasken
40,944 Shares in Edesa Biotech, Inc. (NASDAQ:EDSA) Bought by Citadel Advisors LLC - Defense World
Edesa Biotech Shareholders Approve Key Proposals at AGM - TipRanks
Edesa Biotech (EDSA) Receives Buy Rating from Lucid Capital | ED - GuruFocus
Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech - Defense World
EDSA: Advancing EB06 for the Treatment of Vitiligo - Research Tree
EDSA: Advancing EB06 for the Treatment of Vitiligo… - Yahoo Finance
Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025 - TipRanks
Edesa Biotech Q2 EPS USD -0.3 - marketscreener.com
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development Efforts - Nasdaq
Edesa Biotech Advances Novel Vitiligo Treatment with $15M Backing from Healthcare Investors - Stock Titan
Edesa Biotech Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) to Release Quarterly Earnings on Friday - Defense World
Edesa Biotech to Present at 2024 Bloom Burton Healthcare Investor Conference - TipRanks
Edesa Biotech Inc Azioni (EDSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):